Landscape Capital Management L.L.C. Invests $235,000 in Thermo Fisher Scientific Inc. (NYSE:TMO)

Landscape Capital Management L.L.C. purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund purchased 380 shares of the medical research company’s stock, valued at approximately $235,000.

Several other institutional investors also recently modified their holdings of the business. Intech Investment Management LLC grew its position in shares of Thermo Fisher Scientific by 8.8% during the 3rd quarter. Intech Investment Management LLC now owns 3,417 shares of the medical research company’s stock worth $2,114,000 after buying an additional 275 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in Thermo Fisher Scientific by 4.5% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 180,801 shares of the medical research company’s stock valued at $111,838,000 after purchasing an additional 7,727 shares during the period. Citizens Financial Group Inc. RI grew its holdings in Thermo Fisher Scientific by 1.6% during the third quarter. Citizens Financial Group Inc. RI now owns 27,816 shares of the medical research company’s stock valued at $17,212,000 after purchasing an additional 443 shares during the period. Altman Advisors Inc. acquired a new position in Thermo Fisher Scientific during the third quarter valued at approximately $1,726,000. Finally, Darwin Wealth Management LLC acquired a new position in Thermo Fisher Scientific during the third quarter valued at approximately $270,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on TMO shares. Morgan Stanley boosted their price objective on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an “overweight” rating in a report on Friday, September 20th. UBS Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a report on Monday, September 16th. Stephens initiated coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, October 1st. They issued an “overweight” rating and a $680.00 price target on the stock. Robert W. Baird cut their price target on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Finally, Wells Fargo & Company cut their price target on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $649.33.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $514.05 on Tuesday. The company has a market cap of $196.62 billion, a price-to-earnings ratio of 32.23, a PEG ratio of 3.39 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 1-year low of $480.57 and a 1-year high of $627.88. The company’s fifty day simple moving average is $573.70 and its 200 day simple moving average is $579.75. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The business had revenue of $10.60 billion for the quarter, compared to the consensus estimate of $10.63 billion. During the same period in the previous year, the company earned $5.69 earnings per share. The firm’s revenue for the quarter was up .2% on a year-over-year basis. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 21.67 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be issued a $0.39 dividend. The ex-dividend date of this dividend is Friday, December 13th. This represents a $1.56 annualized dividend and a dividend yield of 0.30%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.78%.

Thermo Fisher Scientific declared that its board has approved a share repurchase program on Friday, November 15th that allows the company to buyback $4.00 billion in outstanding shares. This buyback authorization allows the medical research company to repurchase up to 2% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s board believes its shares are undervalued.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $168,048.00. Following the transaction, the executive vice president now directly owns 16,663 shares of the company’s stock, valued at approximately $9,333,946.08. This trade represents a 1.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the transaction, the senior vice president now directly owns 12,736 shares in the company, valued at approximately $7,134,197.76. This represents a 13.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 37,150 shares of company stock worth $20,651,865 over the last ninety days. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.